Trastuzumab Emtansine
Advanced Malignant Solid Tumors
Puma Biotechnology, Inc.antibody_drug_conjugatePhase 1/2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 73/ 100
Competitive context
37 Active assets in the Advanced Malignant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Neratinib Puma Biotechnology, Inc. | Phase 1/2 | B |
Capecitabine Puma Biotechnology, Inc. | Phase 1/2 | B |
TRASTUZUMAB Puma Biotechnology, Inc. | Phase 1/2 | B |
Vinorelbine Puma Biotechnology, Inc. | Phase 1/2 | B |
js207 Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Trastuzumab Emtansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →